GlassScriptPhysician profile
Richard Sanchez
NPI 1144666207
$17,478.23
in general payments reported to CMS, 2019-2025
19 companies · $1,894 in 2025
The $1,894 reported for 2025 was more than what 83% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,012 · 2020: $745 · 2021: $2,802 · 2022: $3,322 · 2023: $2,145 · 2024: $1,558 · 2025: $1,894.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,597.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,596.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $4,863.50 | 2019-2025 | Cardiomems, Diamondback Peripheral, Esprit |
| Medtronic Vascular, INC. | $4,368.34 | 2019-2020 | |
| Medtronic, INC. | $2,756.11 | 2019-2025 | Corevalve Evolut R, Micra, Hawkone |
| Penumbra, INC. | $2,389.01 | 2022 | |
| Janssen Pharmaceuticals, INC | $1,007.61 | 2019-2024 | Xarelto |
| Boston Scientific Corporation | $497.74 | 2019-2025 | Cds - Mct/Cem Monitoring, Cds - Other |
| Pfizer INC. | $341.46 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $316.73 | 2023-2025 | Jardiance |
| Cardiovascular Systems INC. | $207.33 | 2020-2023 | Diamondback Peripheral |
| Astrazeneca Pharmaceuticals LP | $160.77 | 2023-2025 | Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $135.31 | 2025 | |
| Ekos Corporation | $119.55 | 2019 | |
| Amgen INC. | $72.30 | 2023-2025 | Repatha, Repatha |
| Abiomed | $64.11 | 2024 | Impella |
| Canon Medical Systems USA, INC. | $62.53 | 2024 | General Device(S) |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scpharmaceuticals INC. | $54.99 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $33.67 | 2025 | Camzyos, Eliquis |
| Novartis Pharmaceuticals Corporation | $13.73 | 2019 | |
| Philips North America LLC | $13.44 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Sanchez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.